MiddleBrook Pharmaceuticals, Inc. (NASDAQ:MBRK) has announced the resignation of James Cavanaugh, Ph.D., Martin Vogelbaum, and Harold Werner from its Board of Directors. The resignations were made effective immediately. The company’s acting president and chief executive officer, Dave Becker, has thanked Cavanaugh, Vogelbaum, and Werner for their contributions to the company. For more information about the resignations, visit http://www.middlebrookpharma.com/. Faith Pomeroy-Ward of MiddleBrook Pharmaceuticals, Inc., may also be reached for further information at 817.837.1208.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
MiddleBrook Pharmaceuticals, Inc., formerly Advancis Pharmaceutical Corporation is a pharmaceutical company focused on developing and commercializing anti-infective drug products that fulfill unmet medical needs. The Company developed a delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. It is approved for the treatment of pharyngitis/tonsillitis secondary to Streptococcus pyogenes, commonly known as strep throat, for adults and pediatric patients age 12 and older. The Company operates in one business segment: prescription pharmaceuticals. The Company markets KEFLEX (Cephalexin, USP) capsules, to wholesalers in capsule formulations.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
